(NE)-N-[(3,4-dichlorophenyl)-phenylmethylidene]hydroxylamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (NE)-N-[(3,4-dichlorophenyl)-phenylmethylidene]hydroxylamine
• 化学式: C₁₃H₉Cl₂NO
• 分子量: 266.12
• InChiKey: AKCGBHRHHLEHNI-DTQAZKPQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  32.6
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS<br/>[FR] MERCAPTOIMIDAZOLES SERVANT D'ANTAGONISTES DU RÉCEPTEUR CCR2
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2006015986A1

  公开（公告）日：2006-02-16

  The present invention relates to a compound of formula (I), a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein R1 represents hydrogen, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxyC1-6alkyl, di(C1-6alkyl)amino C1-6alkyl, aryl or heteroaryl; each R2 independently represents halo, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, polyhalo C1-6alkyl, polyhalo C1-6alkyloxy, cyano, aminocarbonyl, amino, mono-or di(C1-4alkyl)amino, nitro, aryl or aryloxy; R3 represents cyano, C(=O)-O-R5, C(=O)-ΝR6aR6b or C(=O)-R7; or a cyclic ring system; R4 represents hydrogen or C1-6alkyl; n is 1, 2, 3, 4 or 5; R10 represents hydrogen, C1-6alkyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, arylcarbonyl, heteroarylcarbonyl, -C(=0)-NH-R5, -C(=S)-NH-R5 or -S(=O)2-R5. The invention also relates to processes for preparing the compounds of formula (I), their use as CCR2 antagonists and pharmaceutical compositions comprising them.

  本发明涉及一种式(I)的化合物，一种N-氧化物，一种药学上可接受的加合盐，一种季铵盐和其立体化学异构体形式，其中R1代表氢，C1-6烷基，C3-7环烷基，C1-6烷氧基C1-6烷基，二(C1-6烷基)氨基C1-6烷基，芳基或杂环芳基；每个R2独立地代表卤素，C1-6烷基，C1-6烷氧基，C1-6烷硫基，多卤素C1-6烷基，多卤素C1-6烷氧基，氰基，氨基甲酰基，氨基，单或双(C1-4烷基)氨基，硝基，芳基或芳氧基；R3代表氰基，C(=O)-O-R5，C(=O)-ΝR6aR6b或C(=O)-R7；或者是一个环状环系统；R4代表氢或C1-6烷基；n为1、2、3、4或5；R10代表氢，C1-6烷基，C1-6烷基羰基，C1-6烷氧羰基，芳基羰基，杂环芳基羰基，-C(=0)-NH-R5，-C(=S)-NH-R5或-S(=O)2-R5。该发明还涉及制备式(I)化合物的方法，它们作为CCR2拮抗剂的用途以及包含它们的药物组合物。
• [EN] MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS<br/>[FR] MERCAPTOIMIDAZOLES EN TANT QU'AGONISTES DU RECEPTEUR CCR2
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2004069809A1

  公开（公告）日：2004-08-19

  The present invention relates to a compound of formula (I),a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein R1 is hydrogen, C1-6alkyl, C3-7cycloalkyl, aryl or heteroaryl; R2 is halo, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, cyano, aminocarbonyl, amino, mono-or di(C1-4alkyl)amino, nitro, aryl or aryloxy; R3 is hydrogen, cyano, C1-6alkyl optionally substituted with hydroxy, C(=O)-O-R5, C(=O)-NR6aR6b, S(=O)2-NR6aR6b, C(=O)-R7; R4 is hydrogen, cyano, C1-6alkyl optionally substituted with hydroxy, C(=O)-O-R5, C(=O)-NR6aR6b, S(=O)2-NR6aR6b, C(=O)-R7; n is 1, 2, 3, 4 or 5;provided that at least one of R3 or R4 is other than hydrogen; and that if R3 represents C(=O)-OH, C(=O)-O-C1-6alkyl or C(=O)-O-C2-6alkenyl, then R4 is other than hydrogen; and that if R3 represents CH2OH and R1 represents hydrogen, then R4 is other than hydrogen; and that if R3 represents C(=O)-NH-C1-4alkyl-NH2 and R1 represents hydrogen, then R4 is other than hydrogen; and that if R3 represents formula (II) and R1 represents hydrogen, then R4 is other than hydrogen; having CCR2 receptor antagonistic properties. The invention also relates to processes for preparing the compounds of formula (I) and pharmaceutical compositions comprising them.

  本发明涉及一种式(I)的化合物，一种N-氧化物，一种药学上可接受的加合盐，一种季铵盐及其立体化异构体，其中R1是氢，C1-6烷基，C3-7环烷基，芳基或杂环芳基；R2是卤素，C1-6烷基，C1-6烷氧基，C1-6烷硫基，多卤代C1-6烷基，多卤代C1-6烷氧基，氰基，氨基甲酰基，氨基，单或双(C1-4烷基)氨基，硝基，芳基或芳氧基；R3是氢，氰基，C1-6烷基，可选择地取代羟基的C(=O)-O-R5，C(=O)-NR6aR6b，S(=O)2-NR6aR6b，C(=O)-R7；R4是氢，氰基，C1-6烷基，可选择地取代羟基的C(=O)-O-R5，C(=O)-NR6aR6b，S(=O)2-NR6aR6b，C(=O)-R7；n为1、2、3、4或5；但要求R3或R4至少有一个不是氢；如果R3代表C(=O)-OH，C(=O)-O-C1-6烷基或C(=O)-O-C2-6烯基，则R4不是氢；如果R3代表CH2OH且R1代表氢，则R4不是氢；如果R3代表C(=O)-NH-C1-4烷基-NH2且R1代表氢，则R4不是氢；如果R3代表式(II)且R1代表氢，则R4不是氢；具有CCR2受体拮抗性质。该发明还涉及制备式(I)化合物的方法和包含其的药物组合物。
• Mercaptoimidazoles as ccr2 receptor antagonists
  申请人：Van Lommen Rosalia Eugeen Guy

  公开号：US20060058289A1

  公开（公告）日：2006-03-16

  The present invention relates to a compound of formula (I) having CCR2 receptor antagonistic properties, particularly anti-infflammatory properties.

  本发明涉及一种具有 CCR2 受体拮抗特性，特别是抗炎特性的式 (I) 化合物。
• MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1592670A1

  公开（公告）日：2005-11-09
• US7511068B2
  申请人：——

  公开号：US7511068B2

  公开（公告）日：2009-03-31